CytRx Corporation (CYTR)

0.57
0.01 2.19
NASDAQ
Prev Close 0.56
Open 0.55
Day Low/High 0.55 / 0.57
52 Wk Low/High 0.33 / 2.18
Volume 20.81K
Exchange NASDAQ
Shares Outstanding 33.64B
Market Cap 18.76M
Div & Yield N.A. (N.A)

Latest News

CytRx Corporation Leads Revival Of Cytotoxic Therapies With LADR™ Technology Targeting Delivery Directly To The Tumor

CytRx Corporation Leads Revival Of Cytotoxic Therapies With LADR™ Technology Targeting Delivery Directly To The Tumor

LADR™ Scientific Research Published as Cover Story in the Peer Reviewed Journal of Controlled Release, a Leading Journal for Drug Delivery

CytRx Corporation Highlights Majority Of Cancer Patients Do Not Have Targetable Genetic Mutations And Are Therefore Candidates For Chemotherapy

CytRx Corporation Highlights Majority Of Cancer Patients Do Not Have Targetable Genetic Mutations And Are Therefore Candidates For Chemotherapy

Approximately 65% of Patients Do Not Have Targetable Genetic Mutations

CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial

CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial

This New Trial Represents The Fourth NantCell Study Evaluating Aldoxorubicin Combined with Immunotherapy or Cell-Based Therapy

CytRx Corporation Announces Conclusion Of Pre-Clinical Phase For Its Albumin Binding Ultra High Potency LADR™ Drug Candidates And Accompanying Companion Diagnostic

CytRx Corporation Announces Conclusion Of Pre-Clinical Phase For Its Albumin Binding Ultra High Potency LADR™ Drug Candidates And Accompanying Companion Diagnostic

LOS ANGELES, Dec. 21, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private, wholly-owned subsidiary Centurion BioPharma Corporation (the...

CytRx Corporation To Present At The 11th Annual LD Micro Main Event

CytRx Corporation To Present At The 11th Annual LD Micro Main Event

LOS ANGELES, Nov. 28, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that John Caloz, Chief Financial Officer, will present at the 11 th Annual LD Micro...

CytRx Corporation Highlights NantCell Inc's Clinical Data With Aldoxorubicin Presented At The Society For Immunotherapy Of Cancer's 33rd Annual Meeting

CytRx Corporation Highlights NantCell Inc's Clinical Data With Aldoxorubicin Presented At The Society For Immunotherapy Of Cancer's 33rd Annual Meeting

Aldoxorubicin Is Part of the NANT Cancer Vaccine Combinations Which Include Immunotherapy and Cell-based Therapy

CytRx Corporation Reports Third Quarter 2018 Financial Results

CytRx Corporation Reports Third Quarter 2018 Financial Results

Quarter Marked by Centurion's Filing of a Provisional Patent for Breakthrough Personalized Medicine Companion Diagnostic to Accompany LADR Assets

Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline

Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline

Aldoxorubicin Being Studied in NantCell Clinical Trials in Combination with Immune-Based Therapy for the Treatment of Squamous Cell Carcinoma, Metastatic Pancreatic and Triple Negative Breast Cancers

CytRx To Hold Third Quarter 2018 Financial Results Conference Call And Webcast On Friday, November 2, 2018

CytRx To Hold Third Quarter 2018 Financial Results Conference Call And Webcast On Friday, November 2, 2018

LOS ANGELES, Oct. 29, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial results for the quarter ended September 30, 2018 on...

Interesting CYTR Call Options For March 2018

Interesting CYTR Call Options For March 2018

Investors in CytRx Corp saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Goodbye CytRx, Your Game Is Over

Goodbye CytRx, Your Game Is Over

Hope springs eternal, until it's dashed on the rocks and buried at sea.

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

First Week of CYTR September 15th Options Trading

First Week of CYTR September 15th Options Trading

Investors in CytRx Corp saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation

24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation

Law Offices of Howard G. Smith reminds investors of the upcoming  September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm

GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") reminds investors of the September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation ("CytRx" or the "Company") (NASDAQ:CYTR )...

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased CytRx Corporation (NASDAQ:CYTR) securities...

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased CytRx Corporation ("CytRx" or the "Company") (NASDAQ: CYTR) securities between...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation ("CytRx" or the "Company") (NASDAQ: CYTR) ...

Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm

Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased CytRx Corporation (NASDAQ:CYTR) securities...

TheStreet Quant Rating: D- (Sell)